• 1
    Tham DM, Gardner CD, Haskell WL 1998 Clinical review 97: Potential health benefits of dietary phytoestrogens. A review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 83:22232235.
  • 2
    Barnes S, Boersma B, Patel R, Kirk M, Darley-Usmar VM, Kim H, Xu J 2000 Isoflavonoids and chronic disease: Mechanisms of action. Biofactors 12:209215.
  • 3
    Anderson JJ 2001 Soy phytoestrogens, lipid reductions, and atherosclerosis delay in ovariectomized primates. J Clin Endocrinol Metab 86:3940.
  • 4
    Anderson JJ, Garner SC 1998 Phytoestrogens and bone. Baillieres Clin Endocrinol Metab 12:543557.
  • 5
    Adlercreutz H, Mazur W 1997 Phyto-oestrogens and Western diseases. Ann Med 29:95120.
  • 6
    Bhathena SJ, Velasquez MT 2002 Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 76:11911201.
  • 7
    Vincent A, Fitzpatrick LA 2000 Soy isoflavones: Are they useful in menopause? Mayo Clin Proc 75:11741184.
  • 8
    Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der BB, Gustafsson JA 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139:42524263.
  • 9
    Setchell KD 2001 Soy isoflavones—benefits and risks from nature's selective estrogen receptor modulators (SERMs). J Am Coll Nutr 20:354S362S.
  • 10
    Setchell KD 1998 Phytoestrogens: The biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 68:1333S1346S.
  • 11
    Calabrese EJ 2001 Estrogen and related compounds: Biphasic dose responses. Crit Rev Toxicol 31:503515.
  • 12
    Kurzer MS 2003 Phytoestrogen supplement use by women. J Nutr 133:1983S1986S.
  • 13
    Munro IC, Harwood M, Hlywka JJ, Stephen AM, Doull J, Flamm WG, Adlercreutz H 2003 Soy isoflavones: A safety review. Nutr Rev 61:133.
  • 14
    Akiyama T, Ishida I, Nakagawa S, Ogawara H, Watanabe SI, Itoh N, Shibuya M, Fukami Y 1987 Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262:55925595.
  • 15
    Kim H, Peterson TG, Barnes S 1998 Mechanisms of action of the soy isoflavone genistein: Emerging role for its effects via transforming growth factor beta signaling pathways. Am J Clin Nutr 68:1418S1425S.
  • 16
    Barnes S, Kim H, Darley-Usmar V, Patel R, Xu J, Boersma B, Luo M 2000 Beyond ERalpha and ERbeta: Estrogen receptor binding is only part of the isoflavone story. J Nutr 130:656S657S.
  • 17
    Su SJ, Yeh TM, Lei HY, Chow NH 2000 The potential of soybean foods as a chemoprevention approach for human urinary tract cancer. Clin Cancer Res 6:230236.
  • 18
    Cassidy A 2003 Dietary phytoestrogens and bone health. J Br Menopause Soc 9:1721.
  • 19
    Arjmandi BH, Khalil DA, Smith BJ, Lucas EA, Juma S, Payton ME, Wild RA 2003 Soy protein has a greater effect on bone in postmenopausal women not on hormone replacement therapy, as evidenced by reducing bone resorption and urinary calcium excretion. J Clin Endocrinol Metab 88:10481054.
  • 20
    Wuttke W, Jarry H, Becker T, Schultens A, Christoffel V, Gorkow C, Seidlova-Wuttke D 2003 Phytoestrogens: Endocrine disrupters or replacement for hormone replacement therapy? Maturitas 44(Suppl 1):S9S20.
  • 21
    Dang ZC, van Bezooijen RL, Karperien M, Papapoulos SE, Lowik CW 2002 Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesis. J Bone Miner Res 17:394405.
  • 22
    Dang ZC, Audinot V, Papapoulos SE, Boutin JA, Lowik CW 2003 Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. J Biol Chem 278:962967.
  • 23
    Kelly DP 2003 PPARs of the heart: Three is a crowd. Circ Res 92:482484.
  • 24
    Francis GA, Annicotte JS, Auwerx J 2003 PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol 3:186191.
  • 25
    Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN 2003 Peroxisome proliferator-activated receptors. Hypertension 42:664668.
  • 26
    Willson TM, Brown PJ, Sternbach DD, Henke BR 2000 The PPARs: From orphan receptors to drug discovery. J Med Chem 43:527550.
  • 27
    Rosen ED, Spiegelman BM 2001 Ppargamma: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:3773137734.
  • 28
    Gilde AJ, Van Bilsen M 2003 Peroxisome proliferator-activated receptors (PPARS): Regulators of gene expression in heart and skeletal muscle. Acta Physiol Scand 178:425434.
  • 29
    Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS 2002 PPARgamma knockdown by engineered transcription factors: Exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 16:2732.
  • 30
    Lazar MA 2002 Becoming fat. Genes Dev 16:15.
  • 31
    Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM 2003 Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113:159170.
  • 32
    Jackson SM, Demer LL 2000 Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett 471:119124.
  • 33
    He TC, Chan TA, Vogelstein B, Kinzler KW 1999 PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335345.
  • 34
    Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N 2003 Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 133:12381243.
  • 35
    Arliss RM, Biermann CA 2002 Do soy isoflavones lower cholesterol, inhibit atherosclerosis, and play a role in cancer prevention? Holist Nurs Pract 16:4048.
  • 36
    Wu X, Peters JM, Gonzalez FJ, Prasad HS, Rohrer MD, Gimble JM 2000 Frequency of stromal lineage colony forming units in bone marrow of peroxisome proliferator-activated receptor-alpha-null mice. Bone 26:2126.
  • 37
    Khan E, Abu-Amer Y 2003 Activation of peroxisome proliferator-activated receptor-gamma inhibits differentiation of preosteoblasts. J Lab Clin Med 142:2934.
  • 38
    Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL 1999 Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 74:357371.
  • 39
    Houston KD, Copland JA, Broaddus RR, Gottardis MM, Fischer SM, Walker CL 2003 Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma. Cancer Res 63:12211227.
  • 40
    Wang X, Kilgore MW 2002 Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells. Mol Cell Endocrinol 194:123133.
  • 41
    Zhou S, Turgeman G, Harris SE, Leitman DC, Komm BS, Bodine PV, Gazit D 2003 Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal stem cells. Mol Endocrinol 17:5666.
  • 42
    Jia TL, Wang HZ, Xie LP, Wang XY, Zhang RQ, Zhou S, Turgeman G, Harris SE, Leitman DC, Komm BS, Bodine PV, Gazit D 2003 Daidzein enhances osteoblast growth that may be mediated by increased bone morphogenetic protein (BMP) production. Biochem Pharmacol 65:709715.